← 產業報告目錄

Companion Animal Diagnostic Market by Product (Consumable, Instrument), Technology (Immunodiagnostic, ELISA, PCR Test, Urinalysis, Hematology), Animal Type (Dog, Cat), Application (Clinical Pathology, Virology), End User - Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-02-17頁數 575報告編號 MD7053

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The companion animal diagnostics market is expected to grow from USD 3.56 billion in 2026 to USD 5.40 billion by 2031, at a CAGR of 8.7%. This growth is driven by several key factors shaping the future of diagnostic technology, preventive care, and precision veterinary medicine. A key catalyst is the growing need for sophisticated diagnostic platforms as veterinary healthcare organizations seek to improve the accuracy, speed, and efficiency of current diagnostic processes. With the increasing need for a targeted, data-focused approach in companion animal healthcare, demand for high-quality diagnostic platforms is rising. Moreover, the need to shift focus to preventive healthcare and targeted disease management is being fueled by the growing demand for innovative diagnostic platforms. This trend is being augmented by AI-driven data analysis and cloud services, resulting in demand for innovative GMP-compliant diagnostic platforms. Furthermore, the increasing incidence of chronic, infectious, and age-related diseases in domesticated pets is fueling the need for rapid, efficient diagnostic options. Veterinarians and veterinary labs are increasingly seeking support from specialty diagnostic companies to meet the ever-rising volume of cases through high-throughput testing, molecular testing, and imaging capabilities. The growing momentum toward modernizing the field of vet care, driven by real-time monitoring tools, artificial intelligence-powered predictive analytics, and cloud-based systems, is also fueling the need for new, high-quality diagnostic services. Advances in technology, including automated analyzers, point-of-care testing, and AI interpretation, are fueling the market by improving test accuracy and turnaround times and expanding testing available in the companion animal space. With more of the companion animal diagnostics space outsourcing expertise in complex animal diagnoses or animal research, these advances also support the continued evolution of the companion animal diagnostics market. "By technology, molecular diagnostics segment to register the highest CAGR during forecast period." The molecular diagnostics segment is expected to see the highest growth in the companion animal diagnostics market due to its ability to deliver accurate results for infectious diseases, genetic disorders, and cancers in pet animals. Improvements in PCR, next-generation sequencing, and liquid biopsy have increased the use of molecular diagnostics, enabling veterinarians to easily test their patients for complex ailments that were previously hard to identify. Additionally, there is a growing need for precision medicine, which requires precise diagnostic methods to provide tailored treatment plans for pets. "By product, consumables segment accounted for larger market share in 2025." In 2025, the consumables segment dominated the companion animal diagnostics market, as reagents, test kits, and diagnostic strips are indispensable components of most tests performed in veterinary labs and animal health centers. Those consumables are used in everyday tests conducted for companion animals, including blood and urinalysis tests. Point-of-care and in-house testing are also widely adopted in the companion animal industry, and these consumables are used on a day-to-day basis. Furthermore, as the need to test animals increases and vet practices move toward preventive testing, there will be a growing demand for consumables, thereby maintaining their dominant market position. “Asia Pacific to witness highest growth rate during forecast period.” The Asia Pacific region is expected to witness the fastest growth in the companion animal diagnostics market during the forecast period, driven by the growing number of pet lovers who are spending heavily on their pets. With greater awareness of animal health and higher spending capacity among pet owners, the Asia Pacific market is growing rapidly. The increased use of advanced animal diagnostic equipment, such as point-of-care testing and molecular diagnostics, is meeting the need for high-quality diagnostics at affordable prices. Moreover, advances in animal healthcare infrastructure and animal insurance coverage are driving the animal diagnostics market in the Asia Pacific region. Breakdown of supply-side primary interviews: • By Company Type: Tier 1 (60%), Tier 2 (30%), and Tier 3 (10%) • By Designation: C-level Executives (30%), Directors (50%), and Other Designations (20%) • By Region: North America (45%), Europe (15%), Asia Pacific (25%), Latin America (10%), and the Middle East & Africa (5%) Breakdown of demand-side primary interviews: • By End User: Diagnostic Laboratories (45%), Veterinary Hospitals & Clinics (30%), Veterinary Research Institutes & Universities (15%), and Home Care Settings (10%) By Designation: Veterinary Clinicians (47%), Diagnostic Laboratory Directors/Managers (22%), R&D Directors/Product Development Heads (15%), and Others (16%) • By Region: North America (25%), Europe (24%), Asia Pacific (25%), Latin America (11%), and the Middle East & Africa (15%) Research Coverage The market study covers the companion animal diagnostics market in various segments. It aims to estimate the market size and growth potential by product, technology, application, animal type, end user, and region. The study also includes an in-depth competitive analysis of the market's key players, along with their company profiles, key observations on their products and business offerings, recent developments, and key market strategies. Reasons to Buy Report The report can assist established companies and newer or smaller firms in understanding market trends, enabling them to capture a larger share of the market. Firms that acquire the report can implement one or more of the five strategies outlined below. This report provides insights into the following points: • Analysis of key drivers (growth in the companion animal population, rising demand for pet insurance, and increased spending on animal healthcare), restraints (high cost of diagnostic devices, stringent regulations and lengthy approval processes for diagnostic products), opportunities (growing demand for rapid tests and portable instruments for POC diagnostics, integration of AI and ML for enhanced disease diagnosis), and challenges (shortage of veterinary practitioners in emerging markets, barriers to adoption in small clinics) influencing the growth of the companion animal diagnostics market. • Product Development/Innovation: Detailed insights on upcoming technologies and product launches in the companion animal diagnostics market. • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of companion animal diagnostic products across regions. • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the companion animal diagnostics market. • Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the companion animal diagnostics market.
目錄 Table of Contents
1 INTRODUCTION 46 1.1 STUDY OBJECTIVES 46 1.2 MARKET DEFINITION 46 1.3 STUDY SCOPE 46 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 47 1.3.2 INCLUSIONS & EXCLUSIONS 48 1.3.3 YEARS CONSIDERED 49 1.3.4 CURRENCY CONSIDERED 49 1.3.5 UNITS CONSIDERED 49 1.4 MARKET STAKEHOLDERS 49 1.5 SUMMARY OF CHANGES 50 2 EXECUTIVE SUMMARY 53 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 53 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 54 2.3 DISRUPTIVE TRENDS IN COMPANION ANIMAL DIAGNOSTICS MARKET 55 2.4 HIGH-GROWTH SEGMENTS 56 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 57 3 PREMIUM INSIGHTS 58 3.1 COMPANION ANIMAL DIAGNOSTICS MARKET OVERVIEW 58 3.2 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT & COUNTRY (2025) 59 3.3 COMPANION ANIMAL DIAGNOSTICS MARKET: REGIONAL MIX 60 3.4 COMPANION ANIMAL DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 61 3.5 COMPANION ANIMAL DIAGNOSTICS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES 62 4 MARKET OVERVIEW 63 4.1 INTRODUCTION 63 4.2 MARKET DYNAMICS 63 4.2.1 DRIVERS 64 4.2.1.1 Growth in companion animal population 64 4.2.1.2 Increasing demand for pet insurance and growth in animal healthcare expenditure 65 4.2.1.3 Growing number of veterinary practitioners 66 4.2.1.4 Increasing prevalence of infectious, parasitic, and chronic diseases in pets 67   4.2.2 RESTRAINTS 68 4.2.2.1 Rising pet care costs 68 4.2.2.2 Limited access to advanced veterinary diagnostic services in developing regions 69 4.2.3 OPPORTUNITIES 69 4.2.3.1 Growing demand for rapid tests and portable instruments for POC diagnostics 69 4.2.3.2 Utilization of AI and ML for enhanced disease diagnosis 70 4.2.4 CHALLENGES 70 4.2.4.1 Low awareness regarding preventive diagnostics among pet owners in price-sensitive markets 70 4.2.4.2 Regulatory and reimbursement limitations in veterinary healthcare diagnostics 71 4.3 UNMET NEEDS & WHITE SPACES 72 4.3.1 UNMET NEEDS IN COMPANION ANIMAL DIAGNOSTICS MARKET 72 4.3.2 WHITE SPACE OPPORTUNITIES 72 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 73 4.4.1 INTERCONNECTED MARKETS 73 4.4.2 CROSS-SECTOR OPPORTUNITIES 74 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 74 4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 74 5 INDUSTRY TRENDS 75 5.1 PORTER’S FIVE FORCES ANALYSIS 75 5.1.1 THREAT OF NEW ENTRANTS 76 5.1.2 THREAT OF SUBSTITUTES 76 5.1.3 BARGAINING POWER OF SUPPLIERS 77 5.1.4 BARGAINING POWER OF BUYERS 77 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 78 5.2 MACROECONOMIC INDICATORS 78 5.2.1 INTRODUCTION 78 5.2.2 GDP TRENDS & FORECAST 78 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 80 5.2.4 TRENDS IN GLOBAL ANIMAL HEALTH INDUSTRY 80 5.3 VALUE CHAIN ANALYSIS 80 5.4 ECOSYSTEM ANALYSIS 82 5.5 PRICING ANALYSIS 83 5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023–2025 84 5.5.2 AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025 85 5.5.2.1 Average selling price trend of rapid test kits, by region, 2023−2025 86 5.5.2.2 Average selling price trend of ELISA/immunodiagnostic test kits & reagents, by region, 2023−2025 86 5.5.2.3 Average selling price trend of clinical chemistry reagents, clips & cartridges, by region, 2023−2025 86 5.5.2.4 Average selling price trend of blood glucose strips, by region, 2023−2025 87 5.5.2.5 Average selling price trend of hematology analyzers, by region, 2023−2025 87 5.6 TRADE ANALYSIS 87 5.6.1 TRADE DATA FOR HS CODE 9018 88 5.6.1.1 Import data for HS Code 9018 88 5.6.1.2 Export data for HS Code 9018 88 5.6.2 TRADE DATA FOR HS CODE 3822 89 5.6.2.1 Import data for HS Code 3822 89 5.6.2.2 Export data for HS Code 3822 89 5.7 KEY CONFERENCES & EVENTS, 2026–2027 90 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 91 5.9 INVESTMENT & FUNDING SCENARIO 92 5.10 SUCCESS STORIES & REAL-WORLD APPLICATIONS 93 5.10.1 NGS-BASED LIQUID BIOPSY FOR CANINE CANCER DETECTION 93 5.10.2 ADOPTION OF AI-ENABLED POC DIAGNOSTIC PLATFORM FOR PARASITE DETECTION 93 5.10.3 DEVELOPMENT OF SNAP 4DX PLUS TEST FOR RAPID VECTOR-BORNE DISEASE DETECTION 94 5.11 IMPACT OF US TARIFFS—COMPANION ANIMAL DIAGNOSTICS MARKET 94 5.11.1 INTRODUCTION 94 5.11.2 KEY TARIFF RATES 96 5.11.3 PRICE IMPACT ANALYSIS 97 5.11.4 IMPACT ON COUNTRIES/REGIONS 98 5.11.5 IMPACT ON END-USE INDUSTRIES 99 5.11.5.1 Veterinary Hospitals & Clinics 99 5.11.5.2 Veterinary Reference Laboratories 100 5.11.5.3 Veterinary Research Institutes & Universities 100 5.11.5.4 Home Care Settings 100 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 101 6.1 KEY EMERGING TECHNOLOGIES 101 6.1.1 AI-ENABLED DIAGNOSTICS 101 6.1.2 PORTABLE INSTRUMENTS FOR POC DIAGNOSTIC SERVICES 101 6.2 COMPLEMENTARY TECHNOLOGIES 102 6.2.1 MICROFLUIDIC DEVICES FOR VETERINARY DIAGNOSTICS 102 6.2.2 CRISPR-BASED MOLECULAR DIAGNOSTICS 103 6.3 ADJACENT TECHNOLOGIES 103 6.3.1 WEARABLE BIOSENSORS & REMOTE MONITORING DEVICES 103 6.3.2 BREATH & SALIVA-BASED DIAGNOSTIC TOOLS 104   6.4 TECHNOLOGY/PRODUCT ROADMAP 104 6.4.1 NEAR TERM (2025–2027) 104 6.4.2 MID-TERM (2028–2030) 105 6.4.3 LONG TERM (2030+) 105 6.5 PATENT ANALYSIS 106 6.5.1 PATENT PUBLICATION TRENDS FOR COMPANION ANIMAL DIAGNOSTIC KITS 106 6.5.2 JURISDICTION & TOP APPLICANT ANALYSIS 107 6.6 FUTURE APPLICATIONS 108 6.6.1 AI-DRIVEN PREDICTIVE DIAGNOSTICS 108 6.6.2 FULLY INTEGRATED DIGITAL VETERINARY ECOSYSTEMS 108 6.6.3 PRECISION & PERSONALIZED VETERINARY DIAGNOSTICS 108 6.6.4 REMOTE & HOME-BASED PET HEALTH MONITORING 108 6.6.5 AUTOMATED HIGH-THROUGHPUT VETERINARY LABORATORIES 108 6.7 IMPACT OF AI/GENERATIVE AI ON COMPANION ANIMAL DIAGNOSTICS MARKET 109 6.7.1 INTRODUCTION 109 6.7.2 MARKET POTENTIAL IN COMPANION ANIMAL DIAGNOSTIC ECOSYSTEM 109 6.7.3 AI USE CASES 110 6.7.4 KEY COMPANIES IMPLEMENTING AI IN COMPANION ANIMAL DIAGNOSTICS MARKET 110 7 REGULATORY LANDSCAPE & SUSTAINABILITY INITIATIVES 112 7.1 REGIONAL REGULATIONS & COMPLIANCE 112 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 113 7.1.1.1 North America 113 7.1.1.2 Europe 114 7.1.1.3 Rest of the world 115 7.1.2 INDUSTRY STANDARDS 116 7.2 SUSTAINABILITY INITIATIVES 117 7.2.1 RECYCLED AND ECO-FRIENDLY MATERIALS FOR COMPANION ANIMAL DIAGNOSTIC PRODUCTS 117 7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 117 7.2.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 118 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 119 8.1 KEY STAKEHOLDERS & BUYING CRITERIA 119 8.1.1 KEY STAKEHOLDERS IN BUYING PROCESS 119 8.1.2 BUYING CRITERIA 120 8.2 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 121 8.2.1 DECISION-MAKING PROCESS 121 8.2.2 ADOPTION BARRIERS & INTERNAL CHALLENGES 122 8.2.3 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 122 8.2.4 MARKET PROFITABILITY 123 9 COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT 124 9.1 INTRODUCTION 125 9.2 CONSUMABLES 125 9.2.1 RECURRING NATURE TO BOOST DEMAND 125 9.3 INSTRUMENTS 128 9.3.1 INCREASING DEMAND FOR POC ANALYZERS TO DRIVE MARKET 128 10 COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY 131 10.1 INTRODUCTION 132 10.2 IMMUNODIAGNOSTICS 132 10.2.1 LATERAL FLOW ASSAYS 136 10.2.1.1 Rapid tests 138 10.2.1.1.1 Growing prevalence of infectious diseases in pets to fuel demand 138 10.2.1.1.2 Global volume analysis of rapid tests, 2024–2031 (thousand units) 140 10.2.1.2 Strip readers 140 10.2.1.2.1 Advancements in digital and AI-enabled diagnostics to support adoption 140 10.2.1.2.2 Global volume analysis of strip readers, 2024–2031 (thousand units) 142 10.2.2 ELISA TESTS 143 10.2.2.1 Higher sensitivity and specificity of ELISA testing to support market expansion 143 10.2.3 ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS 145 10.2.3.1 Rising incidence of allergies and dermatological conditions to fuel market growth 145 10.2.4 IMMUNOASSAY ANALYZERS 147 10.2.4.1 Increasing automation in veterinary diagnostics to drive market growth 147 10.2.5 RADIOIMMUNOASSAYS 149 10.2.5.1 Growing demand for sensitive hormone and endocrine testing to fuel market 149 10.2.6 OTHER IMMUNODIAGNOSTICS PRODUCTS 151 10.3 CLINICAL BIOCHEMISTRY 152 10.3.1 CLINICAL CHEMISTRY ANALYSIS 155 10.3.1.1 Clinical chemistry reagents, clips, and cartridges 157 10.3.1.1.1 Increasing utilization of consumable-based diagnostic workflows to fuel market 157 10.3.1.1.2 Global volume analysis of clinical chemistry reagents, clips, and cartridges, 2024–2031 (thousand units) 159 10.3.1.2 Clinical chemistry analyzers 159 10.3.1.2.1 Growing adoption of in-house veterinary diagnostics to drive analyzer demand 159 10.3.1.2.2 Global volume analysis of clinical chemistry analyzers, 2024–2031 (thousand units) 161 10.3.2 BLOOD GAS & ELECTROLYTE ANALYSIS 162 10.3.2.1 Blood gas and electrolyte reagents, clips, and cartridges 164 10.3.2.1.1 Rising demand for rapid point-of-care consumables to boost market 164 10.3.2.1.2 Global volume analysis of blood gas & electrolyte reagents, clips, and cartridges, 2024–2031 (thousand units) 166 10.3.2.2 Blood gas & electrolyte analyzers 166 10.3.2.2.1 Increasing adoption of compact critical-care analyzers in veterinary clinics to drive market 166 10.3.2.2.2 Global volume analysis of blood gas & electrolyte analyzers, 2024–2031 (thousand units) 168 10.3.3 GLUCOSE MONITORING 169 10.3.3.1 Blood glucose strips 171 10.3.3.1.1 Increasing home-based diabetes management to fuel market 171 10.3.3.1.2 Global volume analysis of blood glucose strips, 2024–2031 (thousand units) 173 10.3.3.2 Glucose monitors 173 10.3.3.2.1 Advancements in portable and continuous glucose monitoring technologies to drive market growth 173 10.3.3.2.2 Global volume analysis of glucose monitors, 2024–2031 (thousand units) 175 10.3.3.3 Urine glucose strips 175 10.3.3.3.1 Cost-effective and non-invasive diabetes screening to propel market 175 10.3.3.3.2 Global volume analysis of urine glucose strips, 2024–2031 (thousand units) 177 10.4 MOLECULAR DIAGNOSTICS 178 10.4.1 PCR TESTS 180 10.4.1.1 Increasing prevalence of infectious diseases in companion animals to support growth 180 10.4.2 MICROARRAYS 183 10.4.2.1 Growing focus on genomic profiling and multiplex testing to drive market 183 10.4.3 NUCLEIC ACID SEQUENCING 184 10.4.3.1 Expanding applications of genomic analysis in veterinary medicine to drive demand 184 10.4.4 OTHER MOLECULAR DIAGNOSTICS PRODUCTS 186 10.5 URINALYSIS 187 10.5.1 URINALYSIS CLIPS & CARTRIDGES 189 10.5.1.1 Growing use of consumable-based urine testing workflows to drive growth 189 10.5.2 URINE ANALYZERS 191 10.5.2.1 Increasing automation in veterinary urinalysis testing to support market growth 191 10.5.3 URINE TEST STRIPS 193 10.5.3.1 Rising demand for rapid and cost-effective urine screening tests to drive market 193 10.6 HEMATOLOGY 195 10.6.1 HEMATOLOGY CARTRIDGES 197 10.6.1.1 Rising use of disposable consumables in automated hematology workflows to fuel demand 197 10.6.2 HEMATOLOGY ANALYZERS 199 10.6.2.1 Growing demand for rapid complete blood count testing to support market growth 199 10.7 OTHER TECHNOLOGIES 201 11 COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION 203 11.1 INTRODUCTION 204 11.2 CLINICAL PATHOLOGY 205 11.2.1 INCREASING PREVENTIVE HEALTH SCREENING AND CHRONIC DISEASE MONITORING DRIVES DEMAND 205 11.3 BACTERIOLOGY 207 11.3.1 RISING BACTERIAL INFECTIONS AND ANTIMICROBIAL RESISTANCE CONCERNS BOOST MARKET GROWTH 207 11.4 VIROLOGY 209 11.4.1 GROWING PREVALENCE OF COMPANION ANIMAL VIRAL DISEASES DRIVES GROWTH 209 11.5 PARASITOLOGY 211 11.5.1 INCREASING PARASITIC AND VECTOR-BORNE DISEASE BURDEN SUPPORTS DIAGNOSTIC ADOPTION 211 11.6 OTHER APPLICATIONS 213 12 COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE 215 12.1 INTRODUCTION 216 12.2 DOGS 217 12.2.1 RISING PREVALENCE OF CANINE CHRONIC AND VECTOR-BORNE DISEASES DRIVES DIAGNOSTIC DEMAND 217 12.3 CATS 219 12.3.1 GROWING AWARENESS OF FELINE INFECTIOUS AND KIDNEY DISEASES BOOSTS MARKET GROWTH 219 12.4 HORSE 222 12.4.1 INCREASING EQUINE HEALTH MONITORING SUPPORTS DIAGNOSTIC ADOPTION 222 12.5 OTHER COMPANION ANIMALS 224   13 COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER 226 13.1 INTRODUCTION 227 13.2 VETERINARY HOSPITALS & CLINICS 227 13.2.1 EXPANDING ADOPTION OF IN-HOUSE POINT-OF-CARE DIAGNOSTIC SOLUTIONS TO DRIVE MARKET 227 13.3 VETERINARY REFERENCE LABORATORIES 229 13.3.1 RISING DEMAND FOR SPECIALIZED AND HIGH-COMPLEXITY VETERINARY DIAGNOSTIC TESTING TO PROPEL MARKET 229 13.4 VETERINARY RESEARCH INSTITUTES & UNIVERSITIES 231 13.4.1 INCREASING RESEARCH FOCUS ON PRECISION AND MOLECULAR VETERINARY DIAGNOSTICS TO SUPPORT GROWTH 231 13.5 HOME CARE SETTINGS 233 13.5.1 GROWING ADOPTION OF AT-HOME PET HEALTH MONITORING AND DIAGNOSTIC TECHNOLOGIES TO BOOST DEMAND 233 14 COMPANION ANIMAL DIAGNOSTICS MARKET, BY REGION 235 14.1 INTRODUCTION 236 14.2 NORTH AMERICA 238 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 239 14.2.2 NORTH AMERICA: VOLUME ANALYSIS, BY PRODUCT, 2024–2031 240 14.2.3 US 247 14.2.3.1 Rising preventive pet healthcare spending to drive market 247 14.2.4 CANADA 253 14.2.4.1 Increasing veterinary visits and growing pet population to drive market 253 14.3 EUROPE 260 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 260 14.3.2 EUROPE: VOLUME ANALYSIS, BY PRODUCT, 2024–2031 261 14.3.3 GERMANY 268 14.3.3.1 Large companion animal population and premium veterinary care fuel market growth 268 14.3.4 UK 275 14.3.4.1 High veterinary expenditure and rising chronic pet diseases support diagnostics demand 275 14.3.5 FRANCE 281 14.3.5.1 Willingness of pet owners to spend on pet health to drive market 281 14.3.6 ITALY 287 14.3.6.1 Expansion of veterinary services supports market growth 287 14.3.7 SPAIN 294 14.3.7.1 Growing pet care economy and animal welfare initiatives to fuel market 294 14.3.8 NETHERLANDS 300 14.3.8.1 Developments in veterinary diagnostic products to support market growth 300 14.3.9 SWEDEN 306 14.3.9.1 Growing companion animal care and advanced veterinary infrastructure supporting market growth 306 14.3.10 POLAND 312 14.3.10.1 Expanding veterinary infrastructure and rising pet ownership support market development 312 14.3.11 REST OF EUROPE 318 14.4 ASIA PACIFIC 324 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 325 14.4.2 ASIA PACIFIC: VOLUME ANALYSIS, BY PRODUCT, 2024–2031 327 14.4.3 CHINA 334 14.4.3.1 Growing urban pet population and rising adoption of pet insurance to propel market 334 14.4.4 JAPAN 340 14.4.4.1 Aging pet population and premium veterinary care to support market growth 340 14.4.5 INDIA 347 14.4.5.1 Expanding pet care industry and rising preventive healthcare awareness fuel market growth 347 14.4.6 AUSTRALIA 353 14.4.6.1 High veterinary expenditure and strong pet insurance penetration to support market growth 353 14.4.7 SOUTH KOREA 359 14.4.7.1 Digital veterinary healthcare expansion to drive market 359 14.4.8 THAILAND 365 14.4.8.1 Urban pet adoption and improving veterinary infrastructure to drive market 365 14.4.9 NEW ZEALAND 371 14.4.9.1 Strong animal welfare culture and preventive care trends support market expansion 371 14.4.10 REST OF ASIA PACIFIC 377 14.5 LATIN AMERICA 383 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 383 14.5.2 LATIN AMERICA: VOLUME ANALYSIS, BY PRODUCT, 2024–2031 384 14.5.3 BRAZIL 390 14.5.3.1 Massive companion animal population to boost demand 390 14.5.4 MEXICO 396 14.5.4.1 High pet ownership and expanding veterinary services to support market growth 396 14.5.5 ARGENTINA 402 14.5.5.1 Strong pet humanization and preventive healthcare trends support market growth 402 14.5.6 REST OF LATIN AMERICA 408   14.6 MIDDLE EAST & AFRICA 414 14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 414 14.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS, BY PRODUCT, 2024–2031 415 14.6.3 GCC COUNTRIES 421 14.6.3.1 Kingdom of Saudi Arabia (KSA) 427 14.6.3.1.1 Government initiatives to drive market growth 427 14.6.3.2 United Arab Emirates (UAE) 433 14.6.3.2.1 Premium veterinary services and rising pet ownership to drive market 433 14.6.3.3 Rest of GCC Countries 439 14.6.4 REST OF MIDDLE EAST & AFRICA 445 15 COMPETITIVE LANDSCAPE 451 15.1 OVERVIEW 451 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 451 15.3 REVENUE ANALYSIS, 2021−2025 453 15.4 MARKET SHARE ANALYSIS, 2025 454 15.4.1 RANKING OF KEY MARKET PLAYERS 455 15.4.2 US MARKET SHARE ANALYSIS, 2025 457 15.4.3 EUROPE MARKET SHARE ANALYSIS, 2025 458 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 459 15.5.1 STARS 459 15.5.2 EMERGING LEADERS 459 15.5.3 PERVASIVE PLAYERS 459 15.5.4 PARTICIPANTS 459 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 461 15.5.5.1 Company footprint 461 15.5.5.2 Region footprint 462 15.5.5.3 Product footprint 463 15.5.5.4 Technology footprint 464 15.5.5.5 Animal type footprint 465 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 466 15.6.1 PROGRESSIVE COMPANIES 466 15.6.2 RESPONSIVE COMPANIES 466 15.6.3 DYNAMIC COMPANIES 466 15.6.4 STARTING BLOCKS 466 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 468 15.6.5.1 Detailed list of key startups/SMEs 468 15.6.5.2 Competitive benchmarking of key startups 469 15.7 BRAND/PRODUCT COMPARISON 470 15.8 R&D EXPENDITURE OF KEY PLAYERS 471   15.9 COMPANY VALUATION & FINANCIAL METRICS 471 15.9.1 FINANCIAL METRICS 471 15.9.2 COMPANY VALUATION 472 15.10 COMPETITIVE SCENARIO 472 15.10.1 PRODUCT LAUNCHES & ENHANCEMENTS 472 15.10.2 DEALS 473 15.10.3 EXPANSIONS 474 15.10.4 OTHER DEVELOPMENTS 475 16 COMPANY PROFILES 476 16.1 KEY PLAYERS 476 16.1.1 IDEXX LABORATORIES, INC. 476 16.1.1.1 Business overview 476 16.1.1.2 Products offered 477 16.1.1.3 Recent developments 478 16.1.1.3.1 Product launches & enhancements 478 16.1.1.4 MnM view 480 16.1.1.4.1 Key strengths 480 16.1.1.4.2 Strategic choices 480 16.1.1.4.3 Weaknesses & competitive threats 480 16.1.2 ANTECH DIAGNOSTICS, INC. 481 16.1.2.1 Business overview 481 16.1.2.2 Products offered 482 16.1.2.3 Recent developments 482 16.1.2.3.1 Product launches & approvals 482 16.1.2.3.2 Expansions 483 16.1.2.4 MnM view 484 16.1.2.4.1 Key strengths 484 16.1.2.4.2 Strategic choices 484 16.1.2.4.3 Weaknesses & competitive threats 484 16.1.3 ZOETIS SERVICES LLC 485 16.1.3.1 Business overview 485 16.1.3.2 Products offered 486 16.1.3.3 Recent developments 487 16.1.3.3.1 Product launches & enhancements 487 16.1.3.3.2 Deals 488 16.1.3.3.3 Expansions 489 16.1.3.3.4 Other developments 489 16.1.3.4 MnM view 490 16.1.3.4.1 Key strengths 490 16.1.3.4.2 Strategic choices 490 16.1.3.4.3 Weaknesses & competitive threats 490 16.1.4 FUJIFILM CORPORATION 491 16.1.4.1 Business overview 491 16.1.4.2 Products offered 493 16.1.4.3 MnM view 493 16.1.4.3.1 Key strengths 493 16.1.4.3.2 Strategic choices 494 16.1.4.3.3 Weaknesses & competitive threats 494 16.1.5 THERMO FISHER SCIENTIFIC INC. 495 16.1.5.1 Business overview 495 16.1.5.2 Products offered 496 16.1.5.3 MnM view 497 16.1.5.3.1 Key strengths 497 16.1.5.3.2 Strategic choices 497 16.1.5.3.3 Weaknesses & competitive threats 497 16.1.6 BIOMÉRIEUX 498 16.1.6.1 Business overview 498 16.1.6.2 Products offered 499 16.1.6.3 Recent developments 500 16.1.6.3.1 Product launches & approvals 500 16.1.7 BIONOTE 501 16.1.7.1 Business overview 501 16.1.7.2 Products offered 501 16.1.7.3 Recent developments 504 16.1.7.3.1 Product launches & enhancements 504 16.1.7.3.2 Deals 506 16.1.8 VIRBAC 507 16.1.8.1 Business overview 507 16.1.8.2 Products offered 508 16.1.8.3 Recent developments 509 16.1.8.3.1 Deals 509 16.1.8.3.2 Expansions 510 16.1.9 RANDOX LABORATORIES LTD. 511 16.1.9.1 Business overview 511 16.1.9.2 Products offered 511 16.1.9.3 Recent developments 512 16.1.9.3.1 Deals 512 16.1.9.3.2 Expansions 513 16.1.10 INDICAL BIOSCIENCE GMBH 514 16.1.10.1 Business overview 514 16.1.10.2 Products offered 515 16.1.10.3 Recent developments 516 16.1.10.3.1 Product enhancements 516 16.1.11 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD. 517 16.1.11.1 Business overview 517 16.1.11.2 Products offered 517 16.1.11.3 Recent developments 518 16.1.11.3.1 Product launches 518 16.1.11.3.2 Expansions 519 16.1.12 BOULE 520 16.1.12.1 Business overview 520 16.1.12.2 Products offered 521 16.1.12.3 Recent developments 522 16.1.12.3.1 Product launches 522 16.1.12.3.2 Deals 523 16.1.13 INNOVATIVE DIAGNOSTICS 524 16.1.13.1 Business overview 524 16.1.13.2 Products offered 524 16.1.13.3 Recent developments 526 16.1.13.3.1 Other developments 526 16.1.14 MEGACOR DIAGNOSTIK GMBH 527 16.1.14.1 Business overview 527 16.1.14.2 Products offered 527 16.1.14.3 Recent developments 531 16.1.14.3.1 Product launches & enhancements 531 16.1.15 BIOGAL 533 16.1.15.1 Business overview 533 16.1.15.2 Products offered 533 16.2 OTHER PLAYERS 535 16.2.1 GOLD STANDARD DIAGNOSTICS 535 16.2.2 AGROLABO S.P.A. 536 16.2.3 PRECISION BIOSENSOR, INC. 538 16.2.4 SKYLA CORPORATION 539 16.2.5 FASSISI, GMBH 540 16.2.6 WOODLEY EQUIPMENT COMPANY LTD 541 16.2.7 BIOPANDA REAGENTS LTD 543 16.2.8 SKYER, INC. 544 16.2.9 RING BIOTECHNOLOGY CO., LTD. 545 16.2.10 SHENZHEN BIOEASY BIOTECHNOLOGY, INC. 546   17 RESEARCH METHODOLOGY 548 17.1 RESEARCH DATA 548 17.2 RESEARCH METHODOLOGY DESIGN 548 17.2.1 SECONDARY DATA 549 17.2.1.1 Key data from secondary sources 550 17.2.2 PRIMARY DATA 550 17.2.2.1 Key data from primary sources 551 17.2.2.2 Key industry insights 552 17.3 MARKET SIZE ESTIMATION 554 17.3.1 BOTTOM-UP APPROACH 559 17.4 MARKET BREAKDOWN AND DATA TRIANGULATION 561 17.5 MARKET SHARE ANALYSIS 562 17.5.1 RESEARCH ASSUMPTIONS 562 17.5.2 GROWTH RATE ASSUMPTIONS 562 17.6 RISK ASSESSMENT 563 17.7 RESEARCH LIMITATIONS 563 17.7.1 METHODOLOGY-RELATED LIMITATIONS 563 17.7.2 SCOPE-RELATED LIMITATIONS 563 18 APPENDIX 564 18.1 DISCUSSION GUIDE 564 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 570 18.3 CUSTOMIZATION OPTIONS 572 18.3.1 PRODUCT ANALYSIS 572 18.3.2 COMPANY INFORMATION 572 18.3.3 GEOGRAPHIC ANALYSIS 572 18.3.4 REGIONAL/COUNTRY-LEVEL MARKET SHARE ANALYSIS 572 18.3.5 COUNTRY-LEVEL VOLUME ANALYSIS BY PRODUCT 572 18.3.6 BY PRODUCT MARKET SHARE ANALYSIS (TOP 5 PLAYERS) 572 18.3.7 ANY CONSULT/CUSTOM REQUIREMENTS AS PER CLIENT REQUESTS 572 18.4 RELATED REPORTS 573 18.5 AUTHOR DETAILS 574
圖表清單 List of Tables & Figures
TABLE 1 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD) 49 TABLE 2 NUMBER OF US HOUSEHOLDS THAT OWN A PET IN 2025, BY ANIMAL TYPE (MILLIONS) 64 TABLE 3 AVERAGE PREMIUMS PAID IN US, 2023 VS. 2024 65 TABLE 4 COMPANION ANIMAL DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 76 TABLE 5 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (USD BILLION) 79 TABLE 6 AVERAGE SELLING PRICE TREND OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2023–2025 (USD) 84 TABLE 7 AVERAGE SELLING PRICE TREND OF RAPID TEST KITS, BY REGION, 2023−2025 86 TABLE 8 AVERAGE SELLING PRICE TREND OF ELISA/IMMUNODIAGNOSTIC TEST KITS & REAGENTS, BY REGION, 2023−2025 86 TABLE 9 AVERAGE SELLING PRICE TREND OF CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES, BY REGION, 2023−2025 86 TABLE 10 AVERAGE SELLING PRICE TREND OF BLOOD GLUCOSE STRIPS, BY REGION, 2023−2025 87 TABLE 11 AVERAGE SELLING PRICE TREND OF HEMATOLOGY ANALYZERS, BY REGION, 2023−2025 87 TABLE 12 IMPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND) 88 TABLE 13 EXPORT DATA FOR HS CODE 9018, BY COUNTRY, 2021–2025 (USD THOUSAND) 88 TABLE 14 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021–2025 (USD THOUSAND) 89 TABLE 15 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021–2025 (USD THOUSAND) 89 TABLE 16 COMPANION ANIMAL DIAGNOSTICS MARKET: MAJOR CONFERENCES & EVENTS IN 2026–2027 90 TABLE 17 CASE STUDY 1: NGS-BASED LIQUID BIOPSY FOR CANINE CANCER DETECTION 93 TABLE 18 CASE STUDY 2: ADOPTION OF AI -ENABLED POC DIAGNOSTIC PLATFORM FOR PARASITE DETECTION 93 TABLE 19 CASE STUDY 3: MULTIPLEX ELISA-BASED POC DIAGNOSTIC TEST: TARGETING VECTOR-BORNE DISEASE DETECTION 94 TABLE 20 US-ADJUSTED RECIPROCAL TARIFF RATES 96 TABLE 21 KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR COMPANION ANIMAL DIAGNOSTICS 97 TABLE 22 NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS 98 TABLE 23 ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS 98 TABLE 24 EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS 99 TABLE 25 LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS 99 TABLE 26 COMPANION ANIMAL DIAGNOSTICS MARKET: MAJOR PATENTS 107 TABLE 27 KEY COMPANIES IMPLEMENTING AI IN COMPANION ANIMAL DIAGNOSTICS MARKET 111 TABLE 28 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 113 TABLE 29 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 114 TABLE 30 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 115 TABLE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR COMPANION ANIMAL DIAGNOSTICS PRODUCTS 119 TABLE 32 KEY BUYING CRITERIA FOR TOP THREE END USERS 121 TABLE 33 COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 125 TABLE 34 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC CONSUMABLES 126 TABLE 35 COMPANION ANIMAL DIAGNOSTIC CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 36 KEY PLAYERS PROVIDING COMPANION ANIMAL DIAGNOSTIC INSTRUMENTS 128 TABLE 37 COMPANION ANIMAL DIAGNOSTIC INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 38 COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 132 TABLE 39 KEY PLAYERS PROVIDING IMMUNODIAGNOSTIC TECHNOLOGIES 133 TABLE 40 COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 134 TABLE 41 COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 42 KEY PLAYERS PROVIDING LATERAL FLOW ASSAYS 136 TABLE 43 LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 136 TABLE 44 LATERAL FLOW ASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 45 KEY PLAYERS PROVIDING LATERAL FLOW RAPID TESTS 138 TABLE 46 RAPID TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 47 RAPID TESTS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 140 TABLE 48 KEY PLAYERS PROVIDING LATERAL FLOW STRIP READERS 141 TABLE 49 STRIP READERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 50 STRIP READERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 142 TABLE 51 KEY PLAYERS PROVIDING ELISA TESTS 143 TABLE 52 ELISA TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 53 KEY PLAYERS PROVIDING ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS 145 TABLE 54 ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 55 KEY PLAYERS PROVIDING IMMUNOASSAY ANALYZERS 147 TABLE 56 IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 57 KEY PLAYERS PROVIDING RADIOIMMUNOASSAYS 149 TABLE 58 RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 59 OTHER IMMUNODIAGNOSTICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 60 KEY PLAYERS PROVIDING CLINICAL BIOCHEMISTRY PRODUCTS 152 TABLE 61 COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 153 TABLE 62 COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 63 KEY PLAYERS PROVIDING CLINICAL CHEMISTRY ANALYSIS 155 TABLE 64 CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 156 TABLE 65 CLINICAL CHEMISTRY ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 66 KEY PLAYERS PROVIDING CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES 157 TABLE 67 CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 68 CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 159 TABLE 69 KEY PLAYERS PROVIDING CLINICAL CHEMISTRY ANALYZERS 160 TABLE 70 CLINICAL CHEMISTRY ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 71 CLINICAL CHEMISTRY ANALYZERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 161 TABLE 72 KEY PLAYERS PROVIDING BLOOD GAS & ELECTROLYTE ANALYSIS 162 TABLE 73 BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 162 TABLE 74 BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 75 KEY PLAYERS PROVIDING BLOOD GAS & ELECTROLYTE REAGENTS, CLIPS, AND CARTRIDGES 164 TABLE 76 BLOOD GAS & ELECTROLYTE REAGENTS, CLIPS, AND CARTRIDGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 77 BLOOD GAS & ELECTROLYTE REAGENTS, CLIPS, AND CARTRIDGES MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 166 TABLE 78 KEY PLAYERS PROVIDING BLOOD GAS & ELECTROLYTE ANALYZERS 167 TABLE 79 BLOOD GAS & ELECTROLYTE ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 80 BLOOD GAS & ELECTROLYTE ANALYZERS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 168 TABLE 81 KEY PLAYERS PROVIDING GLUCOSE MONITORING 169 TABLE 82 GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 169 TABLE 83 GLUCOSE MONITORING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 84 KEY PLAYERS PROVIDING BLOOD GLUCOSE STRIPS 171 TABLE 85 BLOOD GLUCOSE STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 86 BLOOD GLUCOSE STRIPS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 173 TABLE 87 KEY PLAYERS PROVIDING GLUCOSE MONITORS 174 TABLE 88 GLUCOSE MONITORS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 89 GLUCOSE MONITORS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 175 TABLE 90 KEY PLAYERS PROVIDING URINE GLUCOSE STRIPS 176 TABLE 91 URINE GLUCOSE STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 92 URINE GLUCOSE STRIPS MARKET, BY REGION, 2024–2031 (THOUSAND UNITS) 177 TABLE 93 KEY PLAYERS PROVIDING MOLECULAR DIAGNOSTICS 178 TABLE 94 COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 179 TABLE 95 COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 96 KEY PLAYERS PROVIDING PCR TESTS 181 TABLE 97 PCR TESTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 98 MICROARRAYS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 99 NUCLEIC ACID SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 100 OTHER MOLECULAR DIAGNOSTICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 101 KEY PLAYERS PROVIDING URINALYSIS PRODUCTS 187 TABLE 102 COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 188 TABLE 103 COMPANION ANIMAL URINALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 104 KEY PLAYERS PROVIDING URINALYSIS CLIPS & CARTRIDGES 190 TABLE 105 URINALYSIS CLIPS & CARTRIDGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 106 KEY PLAYERS PROVIDING URINE ANALYZERS 192 TABLE 107 URINE ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 108 KEY PLAYERS PROVIDING URINE TEST STRIPS 193 TABLE 109 URINE TEST STRIPS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 110 KEY PLAYERS PROVIDING HEMATOLOGY PRODUCTS 195 TABLE 111 COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 196 TABLE 112 COMPANION ANIMAL HEMATOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 113 KEY PLAYERS PROVIDING HEMATOLOGY CARTRIDGES 197 TABLE 114 HEMATOLOGY CARTRIDGES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 198 TABLE 115 KEY PLAYERS PROVIDING HEMATOLOGY ANALYZERS 199 TABLE 116 HEMATOLOGY ANALYZERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 117 KEY PLAYERS PROVIDING OTHER TECHNOLOGIES 201 TABLE 118 OTHER COMPANION ANIMAL DIAGNOSTIC TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 202 TABLE 119 COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 204 TABLE 120 COMPANION ANIMAL DIAGNOSTICS MARKET FOR CLINICAL PATHOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 206 TABLE 121 COMPANION ANIMAL DIAGNOSTICS MARKET FOR BACTERIOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 122 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VIROLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 123 COMPANION ANIMAL DIAGNOSTICS MARKET FOR PARASITOLOGY, BY COUNTRY, 2024–2031 (USD MILLION) 212 TABLE 124 COMPANION ANIMAL DIAGNOSTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 214 TABLE 125 COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 216 TABLE 126 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC PRODUCTS FOR DOGS 217 TABLE 127 COMPANION ANIMAL DIAGNOSTICS MARKET FOR DOGS, BY COUNTRY, 2024–2031 (USD MILLION) 218 TABLE 128 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC PRODUCTS FOR CATS 220 TABLE 129 COMPANION ANIMAL DIAGNOSTICS MARKET FOR CATS, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 130 KEY PLAYERS OFFERING COMPANION ANIMAL DIAGNOSTIC PRODUCTS FOR HORSES 222 TABLE 131 COMPANION ANIMAL DIAGNOSTICS MARKET FOR HORSES, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 132 COMPANION ANIMAL DIAGNOSTICS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2024–2031 (USD MILLION) 225 TABLE 133 COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 227 TABLE 134 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 135 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VETERINARY REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 230 TABLE 136 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VETERINARY RESEARCH INSTITUTES & UNIVERSITIES, BY COUNTRY, 2024–2031 (USD MILLION) 232 TABLE 137 COMPANION ANIMAL DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024–2031 (USD MILLION) 234 TABLE 138 COMPANION ANIMAL DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 236 TABLE 139 COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 237 TABLE 140 NORTH AMERICA: VOLUME ANALYSIS OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, 2024–2031 (THOUSAND UNITS) 240 TABLE 141 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 240 TABLE 142 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 241 TABLE 143 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 241 TABLE 144 NORTH AMERICA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 145 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 146 NORTH AMERICA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 147 NORTH AMERICA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 148 NORTH AMERICA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 243 TABLE 149 NORTH AMERICA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 150 NORTH AMERICA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 151 NORTH AMERICA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 152 NORTH AMERICA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 153 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 245 TABLE 154 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 246 TABLE 155 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 246 TABLE 156 US: KEY MACROINDICATORS 247 TABLE 157 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 248 TABLE 158 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 248 TABLE 159 US: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 160 US: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 249 TABLE 161 US: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 162 US: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 163 US: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 164 US: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 165 US: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 166 US: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 167 US: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 168 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 252 TABLE 169 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 252 TABLE 170 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 253 TABLE 171 CANADA: KEY MACROINDICATORS 254 TABLE 172 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 254 TABLE 173 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 254 TABLE 174 CANADA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 175 CANADA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 176 CANADA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 177 CANADA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 178 CANADA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 179 CANADA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 180 CANADA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 181 CANADA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 182 CANADA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 183 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 258 TABLE 184 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 259 TABLE 185 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 259 TABLE 186 EUROPE: VOLUME ANALYSIS OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, 2024–2031 (THOUSAND UNITS) 261 TABLE 187 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 262 TABLE 188 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 262 TABLE 189 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 263 TABLE 190 EUROPE: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 191 EUROPE: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 264 TABLE 192 EUROPE: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 264 TABLE 193 EUROPE: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 264 TABLE 194 EUROPE: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 195 EUROPE: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 196 EUROPE: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 197 EUROPE: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 198 EUROPE: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 199 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 266 TABLE 200 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 267 TABLE 201 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 267 TABLE 202 GERMANY: KEY MACROINDICATORS 268 TABLE 203 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 269 TABLE 204 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 269 TABLE 205 GERMANY: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 206 GERMANY: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 207 GERMANY: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 208 GERMANY: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 209 GERMANY: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 210 GERMANY: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 211 GERMANY: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 212 GERMANY: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 213 GERMANY: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 273 TABLE 214 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 273 TABLE 215 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 274 TABLE 216 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 274 TABLE 217 UK: KEY MACROINDICATORS 276 TABLE 218 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 276 TABLE 219 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 276 TABLE 220 UK: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 221 UK: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 222 UK: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 223 UK: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 224 UK: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 225 UK: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 226 UK: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 227 UK: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 279 TABLE 228 UK: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 229 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 280 TABLE 230 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 280 TABLE 231 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 281 TABLE 232 FRANCE: KEY MACROINDICATORS 282 TABLE 233 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 282 TABLE 234 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 282 TABLE 235 FRANCE: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 236 FRANCE: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 237 FRANCE: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 238 FRANCE: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 239 FRANCE: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 284 TABLE 240 FRANCE: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 285 TABLE 241 FRANCE: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 285 TABLE 242 FRANCE: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 285 TABLE 243 FRANCE: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 286 TABLE 244 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 286 TABLE 245 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 286 TABLE 246 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 287 TABLE 247 ITALY: KEY MACROINDICATORS 288 TABLE 248 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 288 TABLE 249 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 289 TABLE 250 ITALY: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 251 ITALY: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 252 ITALY: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 253 ITALY: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 254 ITALY: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 255 ITALY: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 256 ITALY: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 257 ITALY: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 258 ITALY: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 259 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 292 TABLE 260 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 293 TABLE 261 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 293 TABLE 262 SPAIN: KEY MACROINDICATORS 294 TABLE 263 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 295 TABLE 264 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 295 TABLE 265 SPAIN: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 266 SPAIN: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 267 SPAIN: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 268 SPAIN: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 269 SPAIN: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 270 SPAIN: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 271 SPAIN: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 272 SPAIN: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 273 SPAIN: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 274 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 299 TABLE 275 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 299 TABLE 276 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 300 TABLE 277 NETHERLANDS: KEY MACROINDICATORS 301 TABLE 278 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 301 TABLE 279 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 301 TABLE 280 NETHERLANDS: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 281 NETHERLANDS: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 282 NETHERLANDS: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 283 NETHERLANDS: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 284 NETHERLANDS: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 285 NETHERLANDS: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 286 NETHERLANDS: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 287 NETHERLANDS: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 288 NETHERLANDS: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 289 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 305 TABLE 290 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 305 TABLE 291 NETHERLANDS: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 306 TABLE 292 SWEDEN: KEY MACROINDICATORS 307 TABLE 293 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 307 TABLE 294 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 307 TABLE 295 SWEDEN: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 308 TABLE 296 SWEDEN: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 308 TABLE 297 SWEDEN: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 298 SWEDEN: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 299 SWEDEN: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 300 SWEDEN: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 301 SWEDEN: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 302 SWEDEN: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 303 SWEDEN: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 304 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 311 TABLE 305 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 311 TABLE 306 SWEDEN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 312 TABLE 307 POLAND: KEY MACROINDICATORS 313 TABLE 308 POLAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 313 TABLE 309 POLAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 313 TABLE 310 POLAND: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 311 POLAND: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 312 POLAND: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 313 POLAND: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 314 POLAND: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 315 POLAND: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 316 POLAND: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 317 POLAND: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 316 TABLE 318 POLAND: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 317 TABLE 319 POLAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 317 TABLE 320 POLAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 317 TABLE 321 POLAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 318 TABLE 322 REST OF EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 319 TABLE 323 REST OF EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 319 TABLE 324 REST OF EUROPE: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 320 TABLE 325 REST OF EUROPE: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 320 TABLE 326 REST OF EUROPE: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 327 REST OF EUROPE: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 328 REST OF EUROPE: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 321 TABLE 329 REST OF EUROPE: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 322 TABLE 330 REST OF EUROPE: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 322 TABLE 331 REST OF EUROPE: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 322 TABLE 332 REST OF EUROPE: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 323 TABLE 333 REST OF EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 323 TABLE 334 REST OF EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 323 TABLE 335 REST OF EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 324 TABLE 336 ASIA PACIFIC: VOLUME ANALYSIS OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, 2024–2031 (THOUSAND UNITS) 327 TABLE 337 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 328 TABLE 338 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 328 TABLE 339 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 329 TABLE 340 ASIA PACIFIC: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 329 TABLE 341 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 342 ASIA PACIFIC: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 343 ASIA PACIFIC: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 344 ASIA PACIFIC: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 345 ASIA PACIFIC: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 346 ASIA PACIFIC: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 347 ASIA PACIFIC: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 332 TABLE 348 ASIA PACIFIC: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 332 TABLE 349 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 332 TABLE 350 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 333 TABLE 351 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 333 TABLE 352 CHINA: KEY MACROINDICATORS 334 TABLE 353 CHINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 335 TABLE 354 CHINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 335 TABLE 355 CHINA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 356 CHINA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 357 CHINA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 358 CHINA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 337 TABLE 359 CHINA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 337 TABLE 360 CHINA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 337 TABLE 361 CHINA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 338 TABLE 362 CHINA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 338 TABLE 363 CHINA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 338 TABLE 364 CHINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 339 TABLE 365 CHINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 339 TABLE 366 CHINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 340 TABLE 367 JAPAN: KEY MACROINDICATORS 341 TABLE 368 JAPAN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 341 TABLE 369 JAPAN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 342 TABLE 370 JAPAN: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 342 TABLE 371 JAPAN: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 343 TABLE 372 JAPAN: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 343 TABLE 373 JAPAN: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 343 TABLE 374 JAPAN: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 375 JAPAN: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 376 JAPAN: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 377 JAPAN: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 345 TABLE 378 JAPAN: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 345 TABLE 379 JAPAN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 345 TABLE 380 JAPAN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 346 TABLE 381 JAPAN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 346 TABLE 382 INDIA: KEY MACROINDICATORS 347 TABLE 383 INDIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 348 TABLE 384 INDIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 348 TABLE 385 INDIA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 349 TABLE 386 INDIA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 349 TABLE 387 INDIA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 350 TABLE 388 INDIA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 350 TABLE 389 INDIA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 350 TABLE 390 INDIA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 351 TABLE 391 INDIA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 351 TABLE 392 INDIA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 351 TABLE 393 INDIA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 352 TABLE 394 INDIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 352 TABLE 395 INDIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 352 TABLE 396 INDIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 353 TABLE 397 AUSTRALIA: KEY MACROINDICATORS 354 TABLE 398 AUSTRALIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 354 TABLE 399 AUSTRALIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 354 TABLE 400 AUSTRALIA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 355 TABLE 401 AUSTRALIA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 355 TABLE 402 AUSTRALIA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 355 TABLE 403 AUSTRALIA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 356 TABLE 404 AUSTRALIA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 356 TABLE 405 AUSTRALIA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 356 TABLE 406 AUSTRALIA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 357 TABLE 407 AUSTRALIA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 357 TABLE 408 AUSTRALIA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 357 TABLE 409 AUSTRALIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 358 TABLE 410 AUSTRALIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 358 TABLE 411 AUSTRALIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 359 TABLE 412 SOUTH KOREA: KEY MACROINDICATORS 359 TABLE 413 SOUTH KOREA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 360 TABLE 414 SOUTH KOREA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 360 TABLE 415 SOUTH KOREA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 361 TABLE 416 SOUTH KOREA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 361 TABLE 417 SOUTH KOREA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 361 TABLE 418 SOUTH KOREA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 362 TABLE 419 SOUTH KOREA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 362 TABLE 420 SOUTH KOREA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 362 TABLE 421 SOUTH KOREA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 363 TABLE 422 SOUTH KOREA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 363 TABLE 423 SOUTH KOREA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 363 TABLE 424 SOUTH KOREA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 364 TABLE 425 SOUTH KOREA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 364 TABLE 426 SOUTH KOREA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 365 TABLE 427 THAILAND: KEY MACROINDICATORS 366 TABLE 428 THAILAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 366 TABLE 429 THAILAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 366 TABLE 430 THAILAND: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 367 TABLE 431 THAILAND: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 367 TABLE 432 THAILAND: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 367 TABLE 433 THAILAND: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 368 TABLE 434 THAILAND: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 368 TABLE 435 THAILAND: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 368 TABLE 436 THAILAND: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 369 TABLE 437 THAILAND: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 369 TABLE 438 THAILAND: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 369 TABLE 439 THAILAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 370 TABLE 440 THAILAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 370 TABLE 441 THAILAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 371 TABLE 442 NEW ZEALAND: KEY MACROINDICATORS 372 TABLE 443 NEW ZEALAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 372 TABLE 444 NEW ZEALAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 372 TABLE 445 NEW ZEALAND: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 373 TABLE 446 NEW ZEALAND: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 373 TABLE 447 NEW ZEALAND: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 373 TABLE 448 NEW ZEALAND: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 374 TABLE 449 NEW ZEALAND: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 374 TABLE 450 NEW ZEALAND: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 374 TABLE 451 NEW ZEALAND: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 375 TABLE 452 NEW ZEALAND: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 375 TABLE 453 NEW ZEALAND: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 375 TABLE 454 NEW ZEALAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 376 TABLE 455 NEW ZEALAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 376 TABLE 456 NEW ZEALAND: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 377 TABLE 457 REST OF ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 377 TABLE 458 REST OF ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 378 TABLE 459 REST OF ASIA PACIFIC: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 378 TABLE 460 REST OF ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 379 TABLE 461 REST OF ASIA PACIFIC: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 379 TABLE 462 REST OF ASIA PACIFIC: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 379 TABLE 463 REST OF ASIA PACIFIC: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 380 TABLE 464 REST OF ASIA PACIFIC: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 380 TABLE 465 REST OF ASIA PACIFIC: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 380 TABLE 466 REST OF ASIA PACIFIC: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 381 TABLE 467 REST OF ASIA PACIFIC: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 381 TABLE 468 REST OF ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 381 TABLE 469 REST OF ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 382 TABLE 470 REST OF ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 382 TABLE 471 LATIN AMERICA: VOLUME ANALYSIS OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, 2024–2031 (THOUSAND UNITS) 384 TABLE 472 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 384 TABLE 473 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 385 TABLE 474 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 385 TABLE 475 LATIN AMERICA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 386 TABLE 476 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 386 TABLE 477 LATIN AMERICA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 386 TABLE 478 LATIN AMERICA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 387 TABLE 479 LATIN AMERICA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 387 TABLE 480 LATIN AMERICA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 387 TABLE 481 LATIN AMERICA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 388 TABLE 482 LATIN AMERICA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 388 TABLE 483 LATIN AMERICA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 388 TABLE 484 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 389 TABLE 485 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 389 TABLE 486 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 390 TABLE 487 BRAZIL: KEY MACROINDICATORS 391 TABLE 488 BRAZIL: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 391 TABLE 489 BRAZIL: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 391 TABLE 490 BRAZIL: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 392 TABLE 491 BRAZIL: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 392 TABLE 492 BRAZIL: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 392 TABLE 493 BRAZIL: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 393 TABLE 494 BRAZIL: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 393 TABLE 495 BRAZIL: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 393 TABLE 496 BRAZIL: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 394 TABLE 497 BRAZIL: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 394 TABLE 498 BRAZIL: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 394 TABLE 499 BRAZIL: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 395 TABLE 500 BRAZIL: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 395 TABLE 501 BRAZIL: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 396 TABLE 502 MEXICO: KEY MACROINDICATORS 397 TABLE 503 MEXICO: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 397 TABLE 504 MEXICO: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 397 TABLE 505 MEXICO: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 398 TABLE 506 MEXICO: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 398 TABLE 507 MEXICO: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 398 TABLE 508 MEXICO: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 399 TABLE 509 MEXICO: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 399 TABLE 510 MEXICO: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 399 TABLE 511 MEXICO: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 400 TABLE 512 MEXICO: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 400 TABLE 513 MEXICO: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 400 TABLE 514 MEXICO: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 401 TABLE 515 MEXICO: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 401 TABLE 516 MEXICO: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 402 TABLE 517 ARGENTINA: KEY MACROINDICATORS 403 TABLE 518 ARGENTINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 403 TABLE 519 ARGENTINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 403 TABLE 520 ARGENTINA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 404 TABLE 521 ARGENTINA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 404 TABLE 522 ARGENTINA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 404 TABLE 523 ARGENTINA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 405 TABLE 524 ARGENTINA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 405 TABLE 525 ARGENTINA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 405 TABLE 526 ARGENTINA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 406 TABLE 527 ARGENTINA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 406 TABLE 528 ARGENTINA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 406 TABLE 529 ARGENTINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 407 TABLE 530 ARGENTINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 407 TABLE 531 ARGENTINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 408 TABLE 532 REST OF LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 408 TABLE 533 REST OF LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 409 TABLE 534 REST OF LATIN AMERICA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 409 TABLE 535 REST OF LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 410 TABLE 536 REST OF LATIN AMERICA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 410 TABLE 537 REST OF LATIN AMERICA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 410 TABLE 538 REST OF LATIN AMERICA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 411 TABLE 539 REST OF LATIN AMERICA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 411 TABLE 540 REST OF LATIN AMERICA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 411 TABLE 541 REST OF LATIN AMERICA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 412 TABLE 542 REST OF LATIN AMERICA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 412 TABLE 543 REST OF LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 412 TABLE 544 REST OF LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 413 TABLE 545 REST OF LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 413 TABLE 546 MIDDLE EAST & AFRICA: VOLUME ANALYSIS OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, 2024–2031 (THOUSAND UNITS) 415 TABLE 547 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 415 TABLE 548 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 416 TABLE 549 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 416 TABLE 550 MIDDLE EAST & AFRICA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 417 TABLE 551 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 417 TABLE 552 MIDDLE EAST & AFRICA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 418 TABLE 553 MIDDLE EAST & AFRICA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 418 TABLE 554 MIDDLE EAST & AFRICA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 418 TABLE 555 MIDDLE EAST & AFRICA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 419 TABLE 556 MIDDLE EAST & AFRICA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 419 TABLE 557 MIDDLE EAST & AFRICA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 419 TABLE 558 MIDDLE EAST & AFRICA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 420 TABLE 559 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 420 TABLE 560 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 420 TABLE 561 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 421 TABLE 562 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 421 TABLE 563 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 422 TABLE 564 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 422 TABLE 565 GCC COUNTRIES: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 423 TABLE 566 GCC COUNTRIES: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 423 TABLE 567 GCC COUNTRIES: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 423 TABLE 568 GCC COUNTRIES: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 424 TABLE 569 GCC COUNTRIES: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 424 TABLE 570 GCC COUNTRIES: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 424 TABLE 571 GCC COUNTRIES: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 425 TABLE 572 GCC COUNTRIES: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 425 TABLE 573 GCC COUNTRIES: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 425 TABLE 574 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 426 TABLE 575 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 426 TABLE 576 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 427 TABLE 577 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS 427 TABLE 578 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 428 TABLE 579 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 428 TABLE 580 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 429 TABLE 581 KINGDOM OF SAUDI ARABIA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 429 TABLE 582 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 430 TABLE 583 KINGDOM OF SAUDI ARABIA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 430 TABLE 584 KINGDOM OF SAUDI ARABIA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 430 TABLE 585 KINGDOM OF SAUDI ARABIA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 431 TABLE 586 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 431 TABLE 587 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 431 TABLE 588 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 432 TABLE 589 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 432 TABLE 590 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 432 TABLE 591 KINGDOM OF SAUDI ARABIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 433 TABLE 592 UNITED ARAB EMIRATES: KEY MACROINDICATORS 434 TABLE 593 UAE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 434 TABLE 594 UAE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 434 TABLE 595 UAE: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 435 TABLE 596 UAE: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 435 TABLE 597 UAE: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 435 TABLE 598 UAE: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 436 TABLE 599 UAE: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 436 TABLE 600 UAE: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 436 TABLE 601 UAE: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 437 TABLE 602 UAE: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 437 TABLE 603 UAE: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 437 TABLE 604 UAE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 438 TABLE 605 UAE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 438 TABLE 606 UAE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 439 TABLE 607 REST OF GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 439 TABLE 608 REST OF GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 440 TABLE 609 REST OF GCC COUNTRIES: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 440 TABLE 610 REST OF GCC COUNTRIES: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 441 TABLE 611 REST OF GCC COUNTRIES: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 441 TABLE 612 REST OF GCC COUNTRIES: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 441 TABLE 613 REST OF GCC COUNTRIES: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 442 TABLE 614 REST OF GCC COUNTRIES: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 442 TABLE 615 REST OF GCC COUNTRIES: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 442 TABLE 616 REST OF GCC COUNTRIES: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 443 TABLE 617 REST OF GCC COUNTRIES: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 443 TABLE 618 REST OF GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 443 TABLE 619 REST OF GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 444 TABLE 620 REST OF GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 444 TABLE 621 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 445 TABLE 622 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 446 TABLE 623 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL IMMUNODIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 446 TABLE 624 REST OF MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET, BY TYPE, 2024–2031 (USD MILLION) 447 TABLE 625 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2024–2031 (USD MILLION) 447 TABLE 626 REST OF MIDDLE EAST & AFRICA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 447 TABLE 627 REST OF MIDDLE EAST & AFRICA: GLUCOSE MONITORING MARKET, BY TYPE, 2024–2031 (USD MILLION) 448 TABLE 628 REST OF MIDDLE EAST & AFRICA: BLOOD GAS & ELECTROLYTE ANALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 448 TABLE 629 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 448 TABLE 630 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL URINALYSIS MARKET, BY TYPE, 2024–2031 (USD MILLION) 449 TABLE 631 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL HEMATOLOGY MARKET, BY TYPE, 2024–2031 (USD MILLION) 449 TABLE 632 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 449 TABLE 633 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 450 TABLE 634 REST OF MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 450 TABLE 635 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET 451 TABLE 636 COMPANION ANIMAL DIAGNOSTICS MARKET: DEGREE OF COMPETITION 455 TABLE 637 US COMPANION ANIMAL DIAGNOSTICS MARKET: DEGREE OF COMPETITION 457 TABLE 638 EUROPE COMPANION ANIMAL DIAGNOSTICS MARKET: DEGREE OF COMPETITION 458 TABLE 639 COMPANION ANIMAL DIAGNOSTICS MARKET: REGION FOOTPRINT 462 TABLE 640 COMPANION ANIMAL DIAGNOSTICS MARKET: PRODUCT FOOTPRINT 463 TABLE 641 COMPANION ANIMAL DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT 464 TABLE 642 COMPANION ANIMAL DIAGNOSTICS MARKET: ANIMAL TYPE FOOTPRINT 465 TABLE 643 COMPANION ANIMAL DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 468 TABLE 644 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS 469 TABLE 645 COMPANION ANIMAL DIAGNOSTICS MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–MAY 2026 472 TABLE 646 COMPANION ANIMAL DIAGNOSTICS MARKET: DEALS, JANUARY 2022– APRIL 2026 473 TABLE 647 COMPANION ANIMAL DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2022– APRIL 2026 474 TABLE 648 COMPANION ANIMAL DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2022– APRIL 2026 475 TABLE 649 IDEXX LABORATORIES, INC.: COMPANY OVERVIEW 476 TABLE 650 IDEXX LABORATORIES, INC.: PRODUCTS OFFERED 477 TABLE 651 IDEXX LABORATORIES, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022−MAY 2026 478 TABLE 652 ANTECH DIAGNOSTICS, INC.: COMPANY OVERVIEW 481 TABLE 653 ANTECH DIAGNOSTICS, INC.: PRODUCTS OFFERED 482 TABLE 654 ANTECH DIAGNOSTICS, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2026 482 TABLE 655 ANTECH DIAGNOSTICS, INC.: EXPANSIONS, JANUARY 2022–MAY 2026 483 TABLE 656 ZOETIS SERVICES LLC: COMPANY OVERVIEW 485 TABLE 657 ZOETIS SERVICES LLC: PRODUCTS OFFERED 486 TABLE 658 ZOETIS SERVICES LLC: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022-MAY 2026 487 TABLE 659 ZOETIS SERVICES LLC: DEALS, JANUARY 2022−MAY 2026 488 TABLE 660 ZOETIS SERVICES LLC: EXPANSIONS, JANUARY 2022−MAY 2026 489 TABLE 661 ZOETIS SERVICES LLC: OTHER DEVELOPMENTS, JANUARY 2022−MAY 2026 489 TABLE 662 FUJIFILM CORPORATION: COMPANY OVERVIEW 491 TABLE 663 FUJIFILM CORPORATION: PRODUCTS OFFERED 493 TABLE 664 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 495 TABLE 665 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 496 TABLE 666 BIOMÉRIEUX: COMPANY OVERVIEW 498 TABLE 667 BIOMÉRIEUX: PRODUCTS OFFERED 499 TABLE 668 BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2026 500 TABLE 669 BIONOTE: COMPANY OVERVIEW 501 TABLE 670 BIONOTE: PRODUCTS OFFERED 501 TABLE 671 BIONOTE: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–MAY 2026 504 TABLE 672 BIONOTE: DEALS, JANUARY 2022−MAY 2026 506 TABLE 673 VIRBAC: COMPANY OVERVIEW 507 TABLE 674 VIRBAC: PRODUCTS OFFERED 508 TABLE 675 VIRBAC: DEALS, JANUARY 2022–MAY 2026 509 TABLE 676 VIRBAC: EXPANSIONS, JANUARY 2022–MAY 2026 510 TABLE 677 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW 511 TABLE 678 RANDOX LABORATORIES LTD.: PRODUCTS OFFERED 511 TABLE 679 RANDOX LABORATORIES LTD.: DEALS, JANUARY 2022−MAY 2026 512 TABLE 680 RANDOX LABORATORIES LTD.: EXPANSIONS, JANUARY 2022–MAY 2026 513 TABLE 681 INDICAL BIOSCIENCE GMBH: COMPANY OVERVIEW 514 TABLE 682 INDICAL BIOSCIENCE GMBH: PRODUCTS OFFERED 515 TABLE 683 INDICAL BIOSCIENCE GMBH: PRODUCT ENHANCEMENTS, JANUARY 2022−MAY 2026 516 TABLE 684 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 517 TABLE 685 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD.: PRODUCTS OFFERED 517 TABLE 686 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD.: PRODUCT LAUNCHES, JANUARY 2022–MAY 2026 518 TABLE 687 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD.: EXPANSIONS, JANUARY 2022–MAY 2026 519 TABLE 688 BOULE: COMPANY OVERVIEW 520 TABLE 689 BOULE: PRODUCTS OFFERED 521 TABLE 690 BOULE: PRODUCT LAUNCHES, JANUARY 2022–MAY 2026 522 TABLE 691 BOULE: DEALS, JANUARY 2022–MAY 2026 523 TABLE 692 INNOVATIVE DIAGNOSTICS: COMPANY OVERVIEW 524 TABLE 693 INNOVATIVE DIAGNOSTICS: PRODUCTS OFFERED 524 TABLE 694 INNOVATIVE DIAGNOSTICS: OTHER DEVELOPMENTS, JANUARY 2022−MAY 2026 526 TABLE 695 MEGACOR DIAGNOSTIK GMBH: COMPANY OVERVIEW 527 TABLE 696 MEGACOR DIAGNOSTIK GMBH: PRODUCTS OFFERED 527 TABLE 697 MEGACOR DIAGNOSTIK GMBH: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–MAY 2026 531 TABLE 698 BIOGAL: COMPANY OVERVIEW 533 TABLE 699 BIOGAL: PRODUCTS OFFERED 533 TABLE 700 GOLD STANDARD DIAGNOSTICS: COMPANY OVERVIEW 535 TABLE 701 AGROLABO S.P.A.: COMPANY OVERVIEW 536 TABLE 702 PRECISION BIOSENSOR, INC.: COMPANY OVERVIEW 538 TABLE 703 SKYLA CORPORATION: COMPANY OVERVIEW 539 TABLE 704 FASSISI, GMBH: COMPANY OVERVIEW 540 TABLE 705 WOODLEY EQUIPMENT COMPANY LTD: COMPANY OVERVIEW 541 TABLE 706 BIOPANDA REAGENTS LTD.: COMPANY OVERVIEW 543 TABLE 707 SKYER, INC.: COMPANY OVERVIEW 544 TABLE 708 RING BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 545 TABLE 709 SHENZHEN BIOEASY BIOTECHNOLOGY, INC.: COMPANY OVERVIEW 546 TABLE 710 RISK ASSESSMENT ANALYSIS 563 FIGURE 1 COMPANION ANIMAL DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE 47 FIGURE 2 MARKET SCENARIO 53 FIGURE 3 GLOBAL COMPANION ANIMAL DIAGNOSTICS MARKET, 2024–2031 54 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2022–2025 54 FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF COMPANION ANIMAL DIAGNOSTICS MARKET 55 FIGURE 6 HIGH-GROWTH SEGMENTS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2026–2031 56 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN COMPANION ANIMAL DIAGNOSTICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 57 FIGURE 8 RISING COMPANION ANIMAL POPULATION TO FUEL MARKET GROWTH 58 FIGURE 9 CONSUMABLES SEGMENT IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025 59 FIGURE 10 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING THE FORECAST PERIOD 60 FIGURE 11 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 61 FIGURE 12 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 62 FIGURE 13 COMPANION ANIMAL DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63 FIGURE 14 US: PET EXPENDITURE, DOGS VS CATS, 2024 (USD) 66 FIGURE 15 COMPANION ANIMAL DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS 75 FIGURE 16 COMPANION ANIMAL DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 82 FIGURE 17 COMPANION ANIMAL DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 83 FIGURE 18 AVERAGE SELLING PRICE OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2025 (USD) 84 FIGURE 19 AVERAGE SELLING PRICE OF COMPANION ANIMAL DIAGNOSTIC PRODUCTS, BY REGION, 2025 85 FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 91 FIGURE 21 COMPANION ANIMAL DIAGNOSTICS MARKET: INVESTMENT & FUNDING SCENARIO (2021–2025) 92 FIGURE 22 COMPANION ANIMAL DIAGNOSTIC MARKET: NUMBER OF GRANTED PATENT APPLICATIONS (JANUARY 2015–MAY 2026) 106 FIGURE 23 TOP APPLICANT COUNTRIES/REGIONS FOR COMPANION ANIMAL DIAGNOSTIC KITS PATENTS (JANUARY 2015–MAY 2026) 107 FIGURE 24 AI USE CASES 110 FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR COMPANION ANIMAL DIAGNOSTIC PRODUCTS 119 FIGURE 26 KEY BUYING CRITERIA FOR TOP THREE END USERS 120 FIGURE 27 COMPANION ANIMAL DIAGNOSTICS MARKET: GEOGRAPHIC SNAPSHOT 236 FIGURE 28 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET SNAPSHOT 239 FIGURE 29 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET SNAPSHOT 326 FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN THE COMPANION ANIMAL DIAGNOSTICS MARKET (2021−2025) 453 FIGURE 31 MARKET SHARE ANALYSIS OF KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS (2025) 454 FIGURE 32 RANKING OF KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2025 455 FIGURE 33 US: MARKET SHARE ANALYSIS OF KEY PLAYERS (2025) 457 FIGURE 34 EUROPE: MARKET SHARE ANALYSIS OF KEY PLAYERS (2025) 458 FIGURE 35 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 460 FIGURE 36 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPANY FOOTPRINT 461 FIGURE 37 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 467 FIGURE 38 COMPANION ANIMAL DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 470 FIGURE 39 R&D EXPENDITURE OF KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2022−2025 471 FIGURE 40 EV/EBITDA OF KEY VENDORS 471 FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 472 FIGURE 42 IDEXX LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 477 FIGURE 43 ZOETIS SERVICES LLC: COMPANY SNAPSHOT (2025) 486 FIGURE 44 FUJIFILM CORPORATION: COMPANY SNAPSHOT (2025) 492 FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 496 FIGURE 46 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 499 FIGURE 47 VIRBAC: COMPANY SNAPSHOT (2025) 508 FIGURE 48 BOULE: COMPANY SNAPSHOT (2025) 521 FIGURE 49 COMPANION ANIMAL DIAGNOSTICS MARKET: RESEARCH DESIGN 548 FIGURE 50 PRIMARY SOURCES 550 FIGURE 51 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION (SUPPLY SIDE) 552 FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION (DEMAND SIDE) 553 FIGURE 53 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 553 FIGURE 54 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 554 FIGURE 55 REVENUE SHARE ANALYSIS ILLUSTRATION: IDEXX LABORATORIES, INC. 555 FIGURE 56 REVENUE ANALYSIS OF TOP FIVE COMPANIES: COMPANION ANIMAL DIAGNOSTICS MARKET (2025) 555 FIGURE 57 DEMAND-SIDE MARKET ESTIMATION FOR COMPANION ANIMAL DIAGNOSTICS MARKET 557 FIGURE 58 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF COMPANION ANIMAL DIAGNOSTICS MARKET (2026–2031) 558 FIGURE 59 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 558 FIGURE 60 TOP-DOWN APPROACH 559 FIGURE 61 BOTTOM-UP APPROACH 560 FIGURE 62 MARKET DATA TRIANGULATION METHODOLOGY 561

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們